The optimal vascular access for chronic maintenance hemodialysis is the arteriovenous
fistula (AVF). Several studies suggest a role for antiplatelet agents in the prevention of …

Context The arteriovenous fistula is the preferred type of vascular access for hemodialysis
because of lower thrombosis and infection rates and lower health care expenditures …

Vascular access is used as a lifeline for hemodialysis in patients with end stage renal
disease failure (ESRD). Failure of arteriovenous fistula (AVF) maturation is still high. The …

Background The Dialysis Access Consortium (DAC) was developed to investigate
interventions to improve hemodialysis vascular access outcomes. The autogenous …

Background: The most common complication of hemodialysis (HD) access graft is
thrombosis. Clopidogrel, an inhibitor of platelet aggregation, was assessed to prevent this …

BACKGROUND: Hemodialysis vascular access failure occurs often and increases morbidity
for people on hemodialysis therapy. Antiplatelet agents may prevent hemodialysis vascular …

Essentials• Uncertainty remains about antiplatelets for vascular access patency in
hemodialysis patients.• 95 971 people under hemodialysis were followed in a claims …

Background In this study, we evaluated the effects of various medications on the patency of
vascular access (VA) for hemodialysis. Methods We analyzed data from the Longitudinal …

Aims: The aim of this study was to evaluate the impact of antiplatelet agents on the
thrombosis rates of arteriovenous fistulae and grafts used for haemodialysis access …

Thrombosis of hemodialysis vascular access grafts represents a major medical and
economic burden. Experimental and clinical models suggest a role for antiplatelet agents in …